Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate Ulcerative Colitis Clear all
Completed Phase 2 Interventional Results available

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis

NCT03648541
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Hamden, Connecticut • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Dothan, Alabama • Sun City, Arizona • Lancaster, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02171429
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Orlando, Florida • Topeka, Kansas • Mentor, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 10, 2026, 9:18 AM EDT
Recruiting Phase 2 Interventional

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07296315
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Low-dose MH002, High-dose MH002, Placebo
Drug
Lead sponsor
MRM Health NV
Industry
Eligibility
16 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 10, 2026, 9:18 AM EDT
Terminated Phase 1 Interventional

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

NCT03923478
View directory record Official record
Conditions
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Interventions
ABI-M201, Placebo
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Oakland, California • San Carlos, California • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

NCT01461317
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
La Jolla, California • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

NCT04505410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention
Other · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 10, 2026, 9:18 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

NCT03259308
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ontamalimab, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
62
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

NCT01336465
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
placebo, rhuMAb Beta7
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
San Diego, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 4 Interventional

Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis

NCT02345733
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Ulcerative Colitis Diet, Antibiotic cocktail
Other · Drug
Lead sponsor
Prof. Arie Levine
Government
Eligibility
8 Years to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 10, 2026, 9:18 AM EDT
Terminated Phase 3 Interventional Results available

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

NCT02118584
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
57
States / cities
Birmingham, Alabama • La Jolla, California • Orange, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 10, 2026, 9:18 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
52
States / cities
Lancaster, California • Los Angeles, California • Colorado Springs, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 10, 2026, 9:18 AM EDT
Not yet recruiting Phase 4 Interventional

Combination CurQD and Vedolizumab in Ulcerative Colitis

NCT07665294
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
CurQD, Placebo, Vedolizumab
Drug
Lead sponsor
Ryan C Ungaro
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 9:18 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

NCT02520284
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Andecaliximab, Placebo
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Dothan, Alabama • Wheat Ridge, Colorado • Lauderdale Lakes, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

NCT01465763
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Mobile, Alabama • La Jolla, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 10, 2026, 9:18 AM EDT
Recruiting Not applicable Interventional

Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

NCT05987852
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Hyperbaric Oxygen Therapy, Sham Hyperbaric Air
Device · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 10, 2026, 9:18 AM EDT
Terminated Phase 1 Interventional

Bone Marrow Stromal Cells for Inflammatory Bowel Diseases

NCT01851343
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Bone Marrow Stromal Cell (BMSC) Infusion
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 10, 2026, 9:18 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions
Eltrekibart, Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 10, 2026, 9:18 AM EDT
Recruiting Phase 3 Interventional

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

NCT06100289
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 10, 2026, 9:18 AM EDT
Active, not recruiting Phase 2 Interventional

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

NCT05588843
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
SAR443122, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Lancaster, California • Atlanta, Georgia • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

NCT00628433
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, HE3286
Drug
Lead sponsor
Harbor Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Tucson, Arizona • Anaheim, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

NCT01620255
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, PF-00547659 SC Injection
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
99
States / cities
Scottsdale, Arizona • La Jolla, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 10, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Results available

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

NCT04700449
View directory record Official record
Conditions
Moderate to Severe Ulcerative Colitis
Interventions
Double-Blind 0.2mg CBP-307, Double-Blind Placebo, Open-label CBP-307, Double-Blind 0.1mg CBP-307
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Mission Hills, California • Hialeah, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 10, 2026, 9:18 AM EDT